From: Dismukes, Sherry
To: WINKEL Karen J * DCBS
Cc: compliance, statelaw (Gen)
Subject: SB 736 RAC Draft Rules - Oct 5th meeting
Date: Monday, October 11, 2021 12:54:59 PM
Attachments: image001.png

Hi Karen –
During the meeting held on Oct 5th, Numi mentioned those in attendance could provide feedback, comments or questions.
Below are my questions as it relates to the October 5th meeting:

- Disclosure reporting and CE courses:
  - Can the company of the pharmaceutical rep submit disclosure reporting to the state of OR on behalf of the Pharma rep? This is allowed in other states that have disclosure reporting requirements
  - Will disclosure reporting for the state of OR mirror other states like the state of Nevada for example whereby reporting is required annually.
  - Will the state consider removing the duration category as part of the disclosure requirement. This is no longer a requirement for Chicago.
  - Will the state consider removing the TOV associated with samples
  - Since company training courses cannot be used to satisfy OR's CE course requirement, will the state provide clarity around the types of courses that are acceptable and where exactly to go to get training. Chicago provides a link to organizations that provide training and specifies the courses that are acceptable. Will OR do the same.
  - Will the state consider mirroring other state disclosure reporting like the state of Nevada

Best Regards,
Sherry Dismukes
AD, Aggregate Solutions & Gov't Reporting
Ethics, Risks, and Compliance
W+ 862-778-5765
M+ 862-505-6171

From: WINKEL Karen J * DCBS <Karen.J.Winkel@oregon.gov>
Sent: Monday, October 4, 2021 5:16 PM
To: 'anne.murray@bms.com' <anne.murray@bms.com>; 'Alisec@PhRMA.org' <Alisec@PhRMA.org>; 'Bvanhoy@gmhllc.com' <Bvanhoy@gmhllc.com>; 'chloeb@strategies360.com' <chloeb@strategies360.com>; 'Jennifer.Baker2@providence.org' <Jennifer.Baker2@providence.org>; 'mguarino@ospirg.org' <mguarino@ospirg.org>; 'Richard.Blackwell@pacificsource.com' <Richard.Blackwell@pacificsource.com>
Cc: 'simpson.barrie@gene.com' <simpson.barrie@gene.com>; 'wbouska@samhealth.org' <wbouska@samhealth.org>; 'Chelsea.Ott@medprosystems.com' <Chelsea.Ott@medprosystems.com>; 'courtni@theoma.org' <courtni@theoma.org>; 'dtorres@oregonafscme.org' <dtorres@oregonafscme.org>; Dave Nesseler-Cass <dave.nesselercass@modahealth.com>; 'dsavidge@gmhllc.com' <dsavidge@gmhllc.com>; 'Debbie.lavelle@outlook.com' <Debbie.lavelle@outlook.com>; 'ELohnes@ITS.JNJ.com' <ELohnes@ITS.JNJ.com>; 'hasina@grsoregon.com' <hasina@grsoregon.com>; 'gardner.joe@gmail.com' <gardner.joe@gmail.com>; 'jmullin@ocpp.org' <jmullin@ocpp.org>; 'LMendezharper@primetherapeutics.com' <LMendezharper@primetherapeutics.com>; 'LyndaGard@live.com' <LyndaGard@live.com>; 'MAdler@glocomstrategies.com'

<MAdler@glocomstrategies.com>; 'Matt@Markee.org' <Matt@Markee.org>; 'michele@grantspasspharmacy.com' <michele@grantspasspharmacy.com>; 'Richard.Blackwell@pacificsource.com' <Richard.Blackwell@pacificsource.com>; KOSESAN Richard <rkos@rdkcompany.com>; 'robert.judge@modahealth.com' <robert.judge@modahealth.com>; Dallum Rocky <rocky.Dallum@tonkon.com>; Sadie Ellwood <Sadie.T.Ellwood@kp.org>; 'Samantha@oxleyandassociates.com' <Samantha@oxleyandassociates.com>; 'scott@barriehughes.com' <scott@barriehughes.com>; Dismukes, Sherry <sherry.dismukes@novartis.com>; 'TomBusse@protonmail.com' <TomBusse@protonmail.com>; 'vince.porter@cambiahealth.com' <vince.porter@cambiahealth.com>; 'zmccall@lhs.org' <zmccall@lhs.org>

Subject: SB 736 RAC Materials

Importance: High

Attached are the meeting materials for tomorrow's RAC.

Below is the list of committee members:

Anne Murray Bristol-Myers-Squibb

Asher Lisec PhRMA

Brian Van Hoy G&M Health, LLC

Chloe Becker OCAP

Jen Baker Providence

Maribeth Buarino OSPIRG

Rick Blackwell PacificSource

Karen Winkel
Rules Coordinator
DCBS | Division of Financial Regulation
Karen.J.Winkel@dcbs.oregon.gov
Phone: 503-947-7694
Pronouns: she/her/hers